Recombinant Vesicle with pH-Sensitive VSV-G Mutant for Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and immunotherapy, often have significant side effects and limited efficacy due to the difficulty in targeting cancer cells without affecting normal cells and the challenge of making cancer cells recognizable as 'non-self' by the immune system.
Innovation Solution
A recombinant plasma membrane-based vesicle is developed, featuring a VSV-G mutant protein with a histidine substitution to arginine at the 162nd amino acid, which is introduced into the vesicle membrane. This vesicle is designed to induce membrane fusion at physiological pH in cancer cells, promoting cancer cell death and immune recognition without the need for anticancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cancer treatments (chemotherapy, radiation) are used, then cancer cells can be targeted, but normal cells are also affected causing serious side effects
Solution Approach 1:
The exosome membrane is modified with pH-sensitive VSV-G mutant protein that is activated only in the acidic microenvironment of cancer cells (pH 6.5-6.8), while remaining inactive at normal physiological pH (7.4). This spatial differentiation of activity enables selective cancer cell targeting without affecting normal cells.
Solution Approach 2:
The invention exploits the pH parameter difference between tumor microenvironment (acidic) and normal tissue (neutral). The VSV-G mutant protein undergoes conformational change at pH 6.5-6.8, enabling membrane fusion only under acidic conditions, thus achieving selective cancer cell entry.
2Reliability
If traditional immunotherapy is used, then immune response can be stimulated, but effectiveness is limited to less than 30% of patients
Solution Approach 1:
The exosome acts as an intermediary carrier that delivers the VSV-G mutant protein to cancer cells. This mediator enables immune cell recognition of cancer cells as 'non-self' by presenting foreign viral protein on cancer cell surface after membrane fusion, thereby stimulating effective immune response across different cancer types.
Solution Approach 2:
The exosome utilizes its own biological properties (natural ability to fuse with cell membranes) and combines it with the pH-sensitive VSV-G mutant to create a self-activating system that automatically responds to the acidic cancer microenvironment without requiring external activation.
3Quantity of substance
If pH-sensitive VSV-G mutant protein is introduced into exosome membrane, then selective cancer cell targeting is achieved, but the complexity of vesicle production increases
Solution Approach 1:
The invention merges the exosome natural membrane fusion capability with the pH-sensitive VSV-G mutant protein function into a single integrated system. This combination achieves selective cancer cell targeting without requiring complex external control mechanisms or multiple separate components.
Solution Approach 2:
The VSV-G mutant protein serves multiple functions: it acts as a pH sensor, triggers membrane fusion, and provides immune cell recognition signals. This multi-functionality reduces the need for additional components, simplifying the overall vesicle design while maintaining selective targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant vesicle effectively targets and kills cancer cells by inducing membrane fusion at physiological pH, enhancing immune recognition and response, and demonstrating significant anticancer activity in preclinical models without the side effects associated with traditional treatments.
Implementation Method 1
This vesicle is designed to induce membrane fusion at physiological pH in cancer cells
Data Source
AI summary
The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.